GZMA and neoplasm: With correlating gene expression profiles of cytotoxic T lymphocyte (CTL) markers (CD8A, CD8B, GZMA, GZMB, and PRF1) with T-cell characteristics, the TIDE algorithm predicts immunotherapy of tumor patients.